BIIB - Biogen - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062X1037
Multiple Sclerosis, Alzheimer's, Biosimilars, Cancer, Psoriasis
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Web URL: https://www.biogen.com
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for BIIB - Biogen - Stock Price & Dividends](https://www.valueray.com/images/drawdown_chart/BIIB.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for BIIB - Biogen - Stock Price & Dividends](https://www.valueray.com/images/chart/BIIB.NASDAQ_seasonality.png)
BIIB Stock Overview
Market Cap in USD | 33,496m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1991-09-16 |
BIIB Stock Ratings
Growth 5y | -21.6 |
Fundamental | -1.79 |
Dividend | 0.00 |
Rel. Performance vs Sector | -2.52 |
Analysts | 4.17/5 |
Fair Price Momentum | 187.04 USD |
Fair Price DCF | 232.56 USD |
BIIB Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
BIIB Growth Ratios
Growth 12m | -20.38% |
Growth Correlation 12m | -55% |
Growth Correlation 3m | 26% |
CAGR 5y | -2.29% |
CAGR/Mean DD 5y | -0.08 |
Sharpe Ratio 12m | -1.00 |
Alpha vs SP500 12m | -37.70 |
Beta vs SP500 5y weekly | 0.77 |
ValueRay RSI | 24.26 |
Volatility GJR Garch 1y | 25.81% |
Price / SMA 50 | -6.93% |
Price / SMA 200 | -8.61% |
Current Volume | 2255.9k |
Average Volume 20d | 980.9k |
External Links for BIIB Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of BIIB stocks?
As of July 27, 2024, the stock is trading at USD 211.17 with a total of 2,255,900 shares traded.
Over the past week, the price has changed by -6.73%, over one month by -5.92%, over three months by +1.09% and over the past year by -21.84%.
As of July 27, 2024, the stock is trading at USD 211.17 with a total of 2,255,900 shares traded.
Over the past week, the price has changed by -6.73%, over one month by -5.92%, over three months by +1.09% and over the past year by -21.84%.
What are the forecast for BIIB stock price target?
According to ValueRays Forecast Model, BIIB Biogen will be worth about 205.1 in July 2025. The stock is currently trading at 211.17. This means that the stock has a potential downside of -2.88%.
According to ValueRays Forecast Model, BIIB Biogen will be worth about 205.1 in July 2025. The stock is currently trading at 211.17. This means that the stock has a potential downside of -2.88%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 280.4 | 32.8 |
Analysts Target Price | 330.8 | 56.6 |
ValueRay Target Price | 205.1 | -2.88 |